Table 1 Characteristics of the included studies
From: Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis
Author | Study period | Institution/Country | No. of patients | Adjuvant therapy | Outcome | Margin positive | Margin negative | Node positive | Node negative | Stage ≥ II | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Treatment | Control | Therapy | Regimen (details) | Treatment | Control | Treatment | Control | Treatment | Control | Treatment | Control | Treatment | Control | ||||
Lee [12] | 1994–2011 | Korea | 135 | 83 | NSR | FU/GEM(NR) + RT(NR) | OS | <23 % | <37 % | >77 % | >63 % | <27 % | <43 % | >73 % | >57 % | NR | NR |
Subgroup (CT) | 73 | 83 | CT | FU/GEM(NR) | OS | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | ||
Subgroup (CRT) | 62 | 83 | CRT | FU/GEM + RT (NR) | OS | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | ||
Murakami [13] | 1990 to 2010 | Japan | 11 | 51 | CT | GEM + S-1 | OS | NR | NR | NR | NR | NR | NR | NR | NR | ||
Subgroup (stage II/III) | 10 | 31 | CT | (10 cycles every 2 weeks with GEM 700 mg/m2 on day 1 and S-l 50 mg/m2 for 7 consecutive days) | OS | NR | NR | NR | NR | NR | NR | 100 % | 100 % | ||||
Gold [14] | 1985 to 2004 | United States | 25 | 48 | CRT | FU + RT (median dosage 50.4 Gy (range, 19.75–54.0) in 28 fractions and concurrent 5-FU given as an interrupted bolus of 500 mg/m2 for 3 successive days during Week 1 of RT and repeated during Week 5) | OS | 0 | 0 | 100 % | 100 % | 56 % | 13 % | 32 % | 67 % | 80 % | 21 % |
Liang [15] | 1980 to 2005 | China | 62 | 88 | NSR | FU/CF/Adr/Dox/Mi t/Cisp/RT (CT:NR and RT:range 12–66 Gy; mean 51.07 Gy) | OS | NR | NR | NR | NR | NR | NR | 76 % | 92 % | ||
Duffy [16] | 1995 to 2005 | United States | 24 | 99 | NSR | GEM/FU/GEM + Cape + RT(NR) | OS | 0 | 0 | 100 % | 100 % | NR | NR | NR | NR | NR | NR |
CT in 8 PTS, CRT in 16 PTS | |||||||||||||||||
Mojica [17] | 1992 to 2002 | United State (SEER) | 424 | 1901 | RT | NR | OS | NR | NR | NR | NR | 30 % | 15 % | NR | NR | 79 % | 51 % |
Subgroup (Node Positive) | 127 | 277 | RT | RT(NR) | OS | NR | NR | NR | NR | 100 % | 100 % | NR | NR | NR | NR | ||
Subgroup (T3N0) | 71 | 218 | RT | RT (NR) | OS | NR | NR | NR | NR | NR | NR | 100 % | 100 % | NR | NR | ||
Subgroup (T1-2 N0) | 115 | 708 | RT | RT (NR) | OS | NR | NR | NR | NR | NR | NR | 100 % | 100 % | NR | NR | ||
Balacbandran [18] | 1989 to 2000 | India | 73 | 44 | CRT | CRT (NR) | OS | NR | NR | 31 % | 25 % | 13 % | 5 % | 89 % | 86 % | ||
Lindell [19] | 1991 to 1999 | Sweden | 10 | 10 | RT | IORT + EBRT | OS | 50 % | 50 % | NR | NR | 30 % | 20 % | 70 % | 80 % | 80 % | 100 % |
I0RT(20Gy) + EBRT(40Gy, 20 fraction, 5 days a week druing 6 weeks) | |||||||||||||||||
Itoh [20] | 1994 to 2004 | Australia | 5 | 13 | RT | EBRT (total dose of 45. 2 Gy (range, 45. 0–56. 7) for 2–6 weeks, using a fraction size of 1. 8–2. 0 Gy) | OS | 60 % | 31 % | 40 % | 69 % | NR | NR | NR | NR | NR | NR |
Todoroki [21] | 1976 to 1996 | Japan | 47 | 38 | RT | IORT + PORT | OS | 59 % | 50 % | NR | NR | NR | NR | NR | NR | 100 % | 100 % |
Subgroup(Rl) | 28 | 19 | RT | (I0RT(21 ± 0.5Gy, ranging from 15–30 Gy) + P0RT(40 ± 1.9 Gy, ranging from 24.8-54Gy, using a fraction size 1. 8–2.0 Gy)) | OS | 100 % | 100 % | NR | NR | NR | NR | NR | NR | NR | NR | ||